BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  company  Roche  Registration  Ltd.  submitted  on  31  May  1996  to  the  European  Agency  for  the 
Evaluation of Medicinal Products (EMEA), an application to obtain Marketing Authorisation for the 
medicinal  product  Tasmar  tablets  100  and  200  mg  in  accordance  with  the  Centralised  Procedure 
falling  within  the  scope  of  Part  B  of  the  Annex  to  Council  Regulation  No  (EC)  2309/93  of  22  July 
1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were as follows: 
Rapporteur: 
Dr. D. Lyons  
Co-Rapporteur:  Dr. P. Sjöberg 
Licensing status 
The product was not licensed in any country inside or outside the EU at the time of submission of the 
application. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 18 June 1996. 
The  Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on 
15  August  1996.  The  Co-Rapporteur’s  first  assessment  report  was  circulated  to  all  CPMP 
Members on 23 August 1996. 
During the July 1996 CPMP meeting, it was agreed to perform a GMP inspection on the Swiss 
manufacturing facilities for the finished medicinal product. 
During  the  CPMP  plenary  meeting  on  14-17  October  1996,  the  CPMP  agreed  on  the 
consolidated  list  of  questions  to  be  sent  to  the  company.  The  final  consolidated  list  of 
questions was sent to the company on 17 October 1996.  
The  company  submitted 
18 December 1996. 
the  responses 
to 
the  consolidated 
list  of  questions  on 
The  Rapporteur/Co-Rapporteur  circulated  the  joint  assessment  report  on  the  company’s 
responses to the list of questions to all CPMP Members on 17 January 1997. 
A  hearing  was  held  on  18  February  1997,  at  the  CPMP  meeting  to  address  the  remaining 
outstanding  issues  (nephrotoxicity  in  rats,  diarrhoea,  increasing  dyskinesia,  patients  with 
fluctuating  disease,  safety  and  efficacy  in  non-fluctuating  disease).  This  resulted  in 
amendments of the Summary of Product Characteristics, Package Leaflet and Labelling. 
The  Co-Rapporteur,  on  06  March  1997  gave  his  position  on  the  use  of  Tasmar  in  non-
fluctuating Parkinson’s disease patients. 
During its meeting on 17-19 March 1997 the CPMP discussed the recommendations presented 
by  the  Rapporteur,  considering  the  responses  provided  by  the  company  were  satisfactory. 
Amendments were discussed to the Summary of Product Characteristics on the Indications and 
Package Leaflet texts. 
The CPMP issued a positive opinion for granting a Marketing Authorisation to TASMAR 100 
mg and 200 mg film coated tablets, on 19 March 1997. 
1/1 
EMEA 2004 
 
 
 
